# 21 CFR 312.23 IND content and format.

21 CFR 312.23 IND content and format., “IND content and format”, is a CFR section of [21 CFR Part 312, Subpart B—Investigational New Drug Application (IND)](https://ontology.bommaritollc.com/id/01a0f094-b5eb-7044-ac97-26399b822291); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bcdd75647f2a>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter D—DRUGS FOR HUMAN USE](https://ontology.bommaritollc.com/id/01a0f094-b5e4-722f-99b0-5c1856aef2a9) › [21 CFR Part 312—Investigational new drug application](https://ontology.bommaritollc.com/id/01a0f094-b84c-75c3-a0c0-d388d85f1044) › [21 CFR Part 312, Subpart B—Investigational New Drug Application (IND)](https://ontology.bommaritollc.com/id/01a0f094-b5eb-7044-ac97-26399b822291)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-section 21 CFR 312.23](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bce9ee642b6b)
- `eli:cites`:
  - [21 CFR 25.30 General.](https://ontology.bommaritollc.com/id/01a0f094-bb91-7368-898e-36fe349f7c44)
  - [21 CFR 25.31 Human drugs and biologics.](https://ontology.bommaritollc.com/id/01a0f094-bb92-7065-981f-4d5ba7337f0c)
  - [21 CFR 25.40 Environmental assessments.](https://ontology.bommaritollc.com/id/01a0f094-bb96-753f-a17a-23785c940d8f)
  - [21 CFR 50.24 Exception from informed consent requirements for emergency research.](https://ontology.bommaritollc.com/id/01a0f094-bbdb-7063-9b3b-003f585fd3b6)
  - [21 CFR 312.30 Protocol amendments.](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bceb71cf65cc)
  - [21 CFR 312.32 IND safety reporting.](https://ontology.bommaritollc.com/id/01a0f094-c496-70c7-9713-a23940cea934)
  - [21 CFR 312.55 Informing investigators.](https://ontology.bommaritollc.com/id/01a0f094-c4a0-71e7-9113-2757e5a8aa12)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-c493-7765-b5bd-a5f27e59355d)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-e311-76b0-b7ae-4ed679793f6d)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d0-c4d6-7660-84b5-f8d241d5943f)
  - [evidence from https://www.govinfo.gov/link/cfr/21/312?sectionnum=23&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f17-67af-70e0-8a63-2b07f359c513)
- `schema:isPartOf`: [21 CFR Part 312, Subpart B—Investigational New Drug Application (IND)](https://ontology.bommaritollc.com/id/01a0f094-b5eb-7044-ac97-26399b822291)
- `schema:legislationIdentifier`: 21 CFR 312.23
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR section](https://ontology.bommaritollc.com/vocab/leg/cfrSection)
- `schema:name`: IND content and format
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/312?sectionnum=23&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/312?sectionnum=23&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR 312.23 IND content and format.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/312?sectionnum=23&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (11; `eli:cites`):
  - [21 CFR 312.22 General principles of the IND submission.](https://ontology.bommaritollc.com/id/01a0f094-c493-7765-b5bd-a5e5190d9b21)
  - [21 CFR 312.30 Protocol amendments.](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bceb71cf65cc)
  - [21 CFR 312.305 Requirements for all expanded access uses.](https://ontology.bommaritollc.com/id/01a0f094-c4b7-71ba-85f3-71b36f5f1623)
  - [21 CFR 312.33 Annual reports.](https://ontology.bommaritollc.com/id/01a0f094-c497-7027-afdc-26a918b55588)
  - [21 CFR 312.42 Clinical holds and requests for modification.](https://ontology.bommaritollc.com/id/01a0f094-c49a-73d0-9ff1-98da03c4f11e)
  - [21 CFR 312.44 Termination.](https://ontology.bommaritollc.com/id/01a0f094-c49a-73d0-9ff1-98e89a57fab5)
  - [21 CFR 312.55 Informing investigators.](https://ontology.bommaritollc.com/id/01a0f094-c4a0-71e7-9113-2757e5a8aa12)
  - [21 CFR 312.8 Charging for investigational drugs under an IND.](https://ontology.bommaritollc.com/id/01a0f094-c490-745d-afa9-814081295d31)
  - [21 CFR 312.88 Safeguards for patient safety.](https://ontology.bommaritollc.com/id/01a0f094-c4b0-7772-a89a-36140c16a20a)
  - [42 CFR 11.10 What definitions apply to this part?](https://ontology.bommaritollc.com/id/01a0f0b4-2ed3-775e-990a-e0c7ff53d07d)
  - [42 CFR 11.28 What constitutes clinical trial registration information?](https://ontology.bommaritollc.com/id/01a0f0b4-2ed8-753a-87d1-ae5ce90cf341)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bcdd75647f2a.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bcdd75647f2a.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bcdd75647f2a.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bcdd75647f2a)
Cite as: 21 CFR 312.23 IND content and format.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c494-74e2-9ba1-bcdd75647f2a
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
